stockrow
Sunday 8 November 2026
Export AMRN’s income statement to Excel — free account
Amarin Corporation PLC
AMRNHealthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
- Revenue
- −20.4%
- EPS
- +103.1%
- Free cash flow
- +172.6%
Quarter to September 2026, against a year earlier
11.61
0.03
+0.26%
Follow AMRN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 130 | 181 | 229 | 430 | 614 | 583 | 369 | 307 | 229 | 214 | 176 | +5.7% | 183 | 189 | 185 | (4.7%) | |
| Gross margin, % | 73.58 | 75.18 | 76.20 | 77.66 | 78.59 | 79.20 | 65.68 | 53.94 | 35.60 | 56.57 | 40.94 | (17.0) pt | ||||||
| EBT | (76) | (55) | (116) | (22) | (17) | 11 | (104) | (54) | (77) | (36) | (17) | (8.0%) | ||||||
| EBT margin, % | (58.72) | (30.27) | (50.76) | (5.23) | (2.81) | 1.94 | (28.12) | (17.49) | (33.77) | (16.87) | (9.73) | +41.9 pt | ||||||
| Net income | (86) | (68) | (116) | (23) | (18) | 8 | (106) | (59) | (82) | (39) | (19) | (8.5%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 12.28 | 13.38 | 15.42 | 25.09 | 32.17 | 29.45 | 18.41 | 15.06 | 11.13 | 10.30 | 8.43 | (1.9%) | |||||
| Earnings | (8.20) | (5.00) | (7.80) | (1.40) | (1.00) | 0.40 | (5.20) | (3.00) | (4.00) | (1.87) | (0.92) | (15.1%) | ||||||
| Cash flow | (6.78) | (2.43) | (6.37) | (0.55) | (1.14) | (3.36) | (8.98) | 0.34 | (1.51) | 0.32 | 1.79 | n/m | ||||||
| Capex | 0.00 | 0.00 | 0.00 | (0.14) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (6.78) | (2.43) | (6.38) | (0.69) | (1.15) | (3.36) | (8.98) | 0.34 | (1.51) | 0.32 | 1.79 | n/m | ||||||
| Book value | (0.85) | (4.81) | 10.25 | 35.52 | 32.87 | 33.69 | 29.68 | 27.09 | 23.66 | 22.13 | 21.28 | n/m | ||||||
| Shares, m | 11 | 14 | 15 | 17 | 19 | 20 | 20 | 20 | 21 | 21 | 21 | +7.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 130.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.0 | |||||
| P/S | 5.03 | 6.34 | 17.65 | 17.09 | 3.04 | 2.29 | 1.29 | 1.18 | 0.87 | 1.36 | 1.37 | 5.6 | ||||||
| P/B | 0.00 | 0.00 | 31.00 | 12.52 | 2.98 | 2.00 | 0.80 | 0.66 | 0.41 | 0.63 | 0.54 | 5.1 | ||||||
| EV/Sales | 5.17 | 6.60 | 16.91 | 15.72 | 2.25 | 1.53 | 0.50 | 0.19 | (0.34) | 0.02 | (0.36) | 4.9 | ||||||
| EV/FCF | (9.36) | (36.41) | (40.89) | (570.08) | (62.75) | (13.45) | (1.03) | 8.69 | 2.48 | 0.78 | (1.69) | (72.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (72) | (33) | (95) | (9) | (22) | (67) | (180) | 7 | (31) | 7 | 37 | n/m | |||||
| Capex | 0 | 0 | 0 | (2) | 0 | 0 | (1) | 0 | — | — | 0 | +1.9% | ||||||
| Free cash flow | (72) | (33) | (95) | (12) | (22) | (67) | (180) | 7 | (31) | 7 | 37 | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 70 | 45 | 221 | 613 | 572 | 508 | 430 | 466 | 415 | 455 | 438 | +23.1% | |||||
| Net debt | 18 | 48 | (170) | (648) | (505) | (458) | (310) | (321) | (295) | (303) | (324) | n/m | ||||||
| Shareholders’ equity | (9) | (65) | 152 | 608 | 628 | 667 | 595 | 552 | 486 | 459 | 444 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (50.76) | (41.31) | (42.55) | (3.57) | (1.95) | 0.76 | (10.83) | (6.88) | (10.83) | (5.72) | (2.96) | +45.0 pt | |||||
| ROIC | (480.23) | 0.00 | 0.00 | 0.00 | (10.02) | 3.14 | (23.18) | (18.29) | (29.94) | (20.04) | (16.57) | +460.2 pt | ||||||
| ROE | 93.18 | 110.45 | (567.80) | (6.32) | (2.97) | 1.19 | (16.76) | (10.30) | (15.83) | (8.21) | (4.24) | (101.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 215 | 241 | 530 | 965 | 1,000 | 560 | 365 | 275 | 275 | 80 | — | (10.4%) | |||||
| Revenue/emp, $m | 0.61 | 0.75 | 0.43 | 0.45 | 0.61 | 1.04 | 1.01 | 1.12 | 0.83 | 2.67 | — | +17.9% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026
Amarin Corporation PLC vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GSK GSK PLC Sponsored ADR | $101.0B | 16.7× | 15.3× | +3.75% (above 0%: growing) | −14.73% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| BIIB Biogen Inc. | $36.1B | 105× | 46.4× | +10.63% (above 0%: growing) | n/m | −69.25% (below 0%: shrinking) | 73.31% | 4.58% | Compare |
| OGN Organon & Co. | $3.6B | 17.3× | 6.2× | −1.75% (below 0%: shrinking) | +1.64% (above 0%: growing) | +118.79% (above 0%: growing) | 55.21% | 23.19% | Compare |
| GRFS Grifols, S.A. | $2.2B | 18.2× | — | +9.37% (above 0%: growing) | +59.78% (above 0%: growing) | +4.11% (above 0%: growing) | 39.56% | 19.22% | Compare |
| AMRN Amarin Corporation PLC | $244.0M | — (loss-making) | — (loss-making) | −20.37% (below 0%: shrinking) | n/m | +172.64% (above 0%: growing) | 40.91% | (5.97%) | |
| NSRX Nasus Pharma Ltd. | $34.1M | — | — | — | — | −486.98% (below 0%: shrinking) | — | — | Compare |
| MIRA MIRA Pharmaceuticals, Inc. | $22.7M | — (loss-making) | — | — | n/m | −50.76% (below 0%: shrinking) | — | 0.00% | Compare |
| SCLX Scilex Holding Company | $12.0M | — (loss-making) | — (loss-making) | −22.78% (below 0%: shrinking) | n/m | −203.76% (below 0%: shrinking) | 51.88% | (385.02%) | Compare |
| MDCX Medicus Pharma Ltd | $3.5M | — (loss-making) | — | — | n/m | −27.70% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.1B | 17.8× | 15.3× | +3.75% | +1.64% | −39.23% | 55.21% | 4.58% |
Pay and ownership Proxy statement filed 10 April 2026
Ownership
Directors and executive officers, together
4.21%
Sarissa Capital Management LP
7.98%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement